A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Abstract Text:

Lode J Swinnen,Cathryn Rankin,Hetty Carraway,Kathy S Albain,Jeannette J Townsend,George Thomas Budd,Julie A Kish,Saul E Rivkin,Deborah T Blumenthal,

Inhibition of DNA excision repair can modulate resistance to cisplatin. Cytosine arabinoside (Ara-C) and hydroxyurea (HU), in combination, inhibit the excision-repair system and removal of platinum-DNA adducts. Marked cytotoxic synergy had been demonstrated in vitro at clinically achievable levels. The three-drug regimen was found to be feasible in clinical pilot studies. A Phase II study in patients with relapsed or progressive anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM) was performed in the Southwest Oncology Group. The primary end point was 6 month survival, historically about 42%. A loading dose of HU 1,260 mg/m(2) IV over 1 h was followed by Ara-C 1,200 mg/m(2) plus HU 5,040 mg/m(2) IV over 12 h, followed by cisplatin 100 mg/m(2) IV over 1 h. A total of 76 patients were registered. The GBM stratum registered 56 patients in a two-stage accrual. Among 51 eligible GBM patients, the 6-month survival probability was 41% (95% CI 28-55%), and median overall survival was 5 months (95% CI 4-6 months). The 6-month progression-free survival probability was 25% (95% CI 14-37%), and median progression-free survival was 2 months (95% CI 2-4 months). One patient achieved a partial response (2%, 95% CI 0-10%), 13 patients had stable disease (25%, 95% CI 14-39%). Twenty-two patients progressed, and 14 were not assessable for response. The AA stratum was closed early after 20 patients due to slow accrual. Among 19 eligible patients, the 6-month survival probability was 58% (95% CI 36-80%), and median overall survival was 7 months (95% CI 7-14 months). The 6-month progression-free survival probability was 26% (95% CI 6-46%), and median progression-free survival was 3 months (95% CI 2-5 months). No responses were seen. Six patients (32%) had stable disease (95% CI 13-57%), 11 progressed, and 2 were not assessable for response. Of the 70 patients evaluable for toxicity, two died of infection. Twenty-three patients (33%) experienced Grade 4 toxicities, primarily hematological. Cisplatin combined with HU and Ara-C did not improve the 6 month survival rate in patients with relapsed or progressive AA or GBM. Significantly more hematological toxicity was seen than expected from cisplatin alone. Although benefit might be possible in a more platinum-sensitive tumor type, further clinical trials with this regimen for patients with glioblastoma multiforme or anaplastic astrocytoma are not justified.

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Publishing Authors By Initials

LJ Swinnen,C Rankin,H Carraway,KS Albain,JJ Townsend,GT Budd,JA Kish,SE Rivkin,DT Blumenthal,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of neuro-oncology

VOLUME: 86

Page Numbers: 353-8

Journal Abbreviation: J. Neurooncol.

ISSN: 0167-594X

DAY: 16

MONTH: 11

YEAR: 2007

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309335

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

AFFILIATION: Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, CRB 2M88, 1650 Orleans Street, Baltimore, MD, 21231, USA, lswinne1@jhmi.edu.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Neurooncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside Ara-C for adult patients with malignant gliomas Southwest Oncology Group S9149 Related Publications

• A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).
• A case of familial benign chronic pemphigus.
• A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex.
• A novel family of C. elegans snRNPs contains proteins associated with trans-splicing.
• Barriers to the provision of smoking cessation services reported by clinicians in underserved communities.
• C. elegans sequences that control trans-splicing and operon pre-mRNA processing.
• Cataract surgery.
• Changes in plasma volume associated with mental stress ischemia in patients with coronary artery disease.
• Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as "Low Risk" Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA).
• Diaphragmatic hiatus hernia with sever iron-deficient anemia.
• Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
• Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA).
• Functional redundancy of worm spliceosomal proteins U1A and U2B''.
• Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men.
• High-normal fasting blood glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men.
• Infant Mortality in New York City.
• Linkage analysis of a cluster-based quantitative phenotype constructed from pulmonary function test data in 27 multigenerational families with multiple asthmatic members.
• Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs.
• Practical aspects of control of dicumarol therapy.
• Prevalence of basic information technology use by U.S. physicians.
• Regulatory circuit based on autogenous activation-repression: roles of C-boxes and spacer sequences in control of the PvuII restriction-modification system.
• Residual risk in statin-treated patients: future therapeutic options.
• Retinal nerve fiber layer split bundles are true anatomic variants.
• Search for quantitative trait loci of atopy-associated immune responses using allergen-specific IgG1 as an "endophenotype".
• Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion.
• Suicidal gunshot wounds to the head: a retrospective review of 406 cases.
• The National Emergency Department Safety Study: study rationale and design.
• The antihistamine drugs in the treatment of hay fever in the adult.
• Trans-splicing and operons.
• WITHDRAWAL OF INTER-RETINAL FLUID IN DETACHMENT OPERATION BY SIMPLE SUCTION APPARATUS.